Fixed-dose combinations of enalapril and hydrochlorothiazide: effects on arterial hypertension treatment. GARANT Study, Part II
Abstract
Aim. To present the results of the GARANT study, Part II, supported by the Society of Cardiology of the Russian Federation. To study the effects of fixed-dose enalapril and hydrochlorothiazide combinations on arterial hypertension (AH) treatment in real(world clinical practice.
Material and methods. The second part of the study included 3188 patients aged 18 years and above, with blood pressure (BP) level ≥160/95 mm Hg or isolated systolic AH, and without previous effective antihypertensive therapy. Mean age of the participants was >55 years, AH duration ~10 years; almost every subject was overweight or had high total cholesterol (TCH) level. More than 70% of the patients had left ventricular hypertrophy, every third suffered from heart disease, and 15,7% had stroke in anamnesis. Most of the patients (87,5%) received Enap HL 20 for 8 weeks. After 2 weeks of the treatment, 4,6% were switched to Enap Н, and 7,9% – to Enap НL.
Results. The treatment was associated with systolic and diastolic BP (SBP, DBP) reduction as early as after the first two weeks: to 142,4±0,3 and 86,4±0,2 mm Hg, respectively. After 8 weeks, these parameters reached 134,5±0,2 and 82,4±0,1 mm Hg, respectively. Heart rate decreased by 5,0±0,1 bpm. After 8 weeks of the treatment, creatinine level did not change, and mean levels of glucose, TCH, uric acid, and potassium significantly reduced.
Conclusion. After 8 weeks, treatment was effective in 53% of the participants. By the end of the study, SBP decrease by 20 mm Hg and DBP decrease by 10 mm Hg was observed in 86%. In total, 223 (6,9%) adverse events were registered. The results demonstrated metabolic neutrality of this antihypertensive combination.
About the Authors
S. A. Shalnova
State Research Center for Preventive Medicine, Federal Agency on High Medical Technologies, Moscow
Russian Federation
Russian Federation
A. D. Deev
State Research Center for Preventive Medicine, Federal Agency on High Medical Technologies, Moscow
Russian Federation
Russian Federation
References
1. Оганов Р.Г. Проблема контроля артериальной гипертонии среди населения. Кардиология 1994; 3: 80-3.
2. Шальнова С.А.Эпидемиология артериальной гипертонии. В кн. Руководство по артериальной гипертонии под ред. Е.И.Чазова и И.Е Чазовой. Москва «Медиа Медика» 2005; 79-94.
3. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996; 275: 1571-6.
4. Mancia G. Role of outcome trials in providing information on antihypetrtensive treatment: importance and limitations. Am J Hypertens 2006; 19: 1-7.
5. Sifkova R, Skodova Z, Lanska V, et al. Trends in slood pressure levels, prevalence, awareness and control of hypertension in the Czech population from 1985 to 2000/01. J Hypertens 2004; 22: 1479-85.
6. Zdrojevski T, Szpakovski P, Bandosz P, et al. Arterial hypertension in Poland in 2002. J Hum Hypertens 2004; 18: 557-62.
7. Primatesta P, Poulter N. Improuvement in hypertension management in England: results from the health survey for England 2003. J Hypertens 2006; 24: 1187-92.
8. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treat-ment and control in hypertension in the United states, 1988-2000. JAMA 2003; 290: 199-206.
9. Simpson SH, Eurich DT, Majumdar SR et al. A meta-analysis of the association between adherence to drug therapy and mortality BMJ 2006; 333: 15 -1 July).
10. Chapman RH, Benner JS, Petrilla AA, et al. Predictors of adherence with antihypertensive and lipid-lowering therapies increases patients adherence. Ann Intern Med 2005; 165: 1147-52.
11. Шальнова С.А., Марцевич С.Ю., Деев А.Д. и др. Сравнительное изучение эффективности спираприла и амлодипина. Результаты рандомизированного исследования у больных мягкой и умеренной артериальной гипертонией. Тер архив 2000; 72(10): 10-3.
12. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European society of hypertension and European society of cardiology. J Hypertes 2007; 25: 1105-87.
13. Шальнова С.А., Деев А.Д, Карпов Ю.А. Артериальная гипертония и ишемическая болезнь сердца в реальной практике врача-кардиолога. Кардиоваск тер профил 2006; 2: 73- 80.
14. Моисеев ВС, Кобалава ЖД. Артериальная гипертония у лиц старших возрастных групп. Москва 2002.
15. Шальнова С.А., Деев А.Д., Вихирева О.В. Артериальная гипертония глазами амбулаторных пациентов. Первые результаты исследования ГАРАНТ. Кардиоваск тер профил 2007; 5: 30-3.
16. SAS/STAT User’s Guide, Version 6, Fourth Edition, Vol.1 & 2, SAS Institute Inc., Cary, NC, USA, 1990.
17. Тимофеева Т.Н., Шальнова СА, Константинов ВВ. и соавт. Распространенность факторов, влияющих на прогноз больных артериальной гипертонией и оценка общего сердечно-сосудистого риска. Кардиоваск тер профил 2005; 4(6) ч.1: 15-24.
18. Чазова ИЕ, Ратова ЛГ, Дмитриев ВВ. и др. Ко-ренитек в лечении умеренной и тяжелой формы течения гипертонической болезни. Тер архив 2003; 7: 21-6.
19. Марцевич С.Ю., Лукина Ю.В., Деев А.Д. и др. Сравнительное изучение комбинированных препаратов эналаприла малеата и гидрохлортиазида: «Рениприла ГТ» и «Ко-ренитека» у больных мягкой и умеренной АГ. РФК 2005; 3: 29-34.
Review
For citations:
Shalnova S.A., Deev A.D. Fixed-dose combinations of enalapril and hydrochlorothiazide: effects on arterial hypertension treatment. GARANT Study, Part II. Cardiovascular Therapy and Prevention. 2007;6(8):28-33. (In Russ.)
Views:
1087
Email this article 
